ArticleFrontiers in global women's health2025
Burden of hypertensive heart disease among women of childbearing age in global, regional, and national regions from 1990 to 2021 and projection until 2040.
Article in Frontiers in global women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The present research focuses on elucidating the global burden of hypertensive heart disease (HHD) among women of childbearing age (WCBA). By utilizing all available data and adopting the methodology employed in the Global Burden of Disease (GBD) study, this study aims to comprehensively analyze the epidemiological characteristics of this highly prevalent disorder. Methods: In this research, we retrieved three key indicators-prevalence, incidence, and DALYs-related to HHD in WCBA from the GBD database for the period 1990 to 2021. Our study provides point estimates along with their corresponding 95% uncertainty intervals (UIs). The evolving trends were assessed using the EAPC and percentage change. Results: In 2021, the global prevalence of HHD among WCBA was 544,544 cases, resulting in 25,669 deaths. Compared to 1990, the prevalence increased by 110%, and mortality rose by 27%. From 1990 to 2021, the prevalence rate showed an upward trend (EAPC: 1.31), whereas the mortality rate exhibited a decline (EAPC: -0.51). In 2021, middle SDI regions recorded the highest prevalence rate (30.88 per 100,000), while low SDI regions had the highest mortality rate (2.44 per 100,000) and the greatest burden of DALYs (125.39 per 100,000). Among different age groups in 2021, the 45-49 age group experienced the highest number of cases (195,288) and the highest prevalence rate (82.87 per 100,000). Furthermore, HHD prevalence demonstrated a positive correlation with age. Conclusion: Overall, on a global scale, the burden of HHD among WCBA has significantly increased over the past 32 years. This trend is particularly pronounced in low SDI regions and within the 45-49 age group. The findings of this study highlight the critical need for targeted interventions to address this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.